Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Genetics Reports Fallen Q1 Revenue as Net Loss Narrows

NEW YORK, May 1 - Paradigm Genetics today reported a decline in first-quarter revenue atop receded R&D spending and narrowed net losses.

 

The ag-genomics company said total revenue for the period ended March 31 fell to $4.1 million from $5.6 million during the same time last year. Income from commercial partnerships in the first quarter 2003 shrank to $3.8 million from $5.6 million year over year, though Paradigm was able to book $228,000 in grant revenue in the quarter.

 

R&D spending also decreased, to $5.8 million in the current first quarter from $7.6 million for the same time one year ago, according to Paradigm. Included in these numbers was $71,000 and $105,000 in stock-based compensation in the 2003 and 2002 periods, respectively.

 

Net loss fell to $4.1 million, or $.13 per share, from $5.2 million, or $.16 per share, year over year, Paradigm said.

 

The company had roughly $11 million in cash, cash equivalents, and short-term investments as of March 31.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.